ERBB2 and breast carcinoma: In a phase 2 clinical trial of postmenopausal patients with hormone receptor positive, HER2-negative advanced breast cancer, dovitinib combined with fulvestrant prolonged progression-free survival in patients with FGF amplification (10.9 vs. 5.5 months) [207].